11-deoxy-11-hydroxyimino-1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 11-deoxy-11-hydroxyimino-1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin
• 化学式: C₅₁H₆₅N₅O₁₃
• 分子量: 956.103
• InChiKey: JRWHZQPUGLPSBE-LWYRXQELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.43
• 重原子数：
  69.0
• 可旋转键数：
  5.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  246.18
• 氢给体数：
  6.0
• 氢受体数：
  17.0

反应信息

• 作为产物：
  描述：

  Rifalazil 在 吡啶 、 盐酸羟胺 作用下， 以 甲醇 为溶剂， 生成 11-deoxy-11-hydroxyimino-1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin
  参考文献：
  名称：

  Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

  摘要：

  We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better than, rifamycin reference agents. In addition, some of the compounds retain potent activity against an intermediate rifamycin-resistant strain of Staphylococcus aureus. For instance, compound 5k exhibits an MIC of 0.12 mu g/mL against an intermediate rifamycin-resistant strain, while the rifamycin reference agents, rifampin and rifalazil, exhibit MICs of 16 mu g/mL and 2 mu g/mL, respectively, against the same strain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.048

文献信息

• US7265107B2
  申请人：——

  公开号：US7265107B2

  公开（公告）日：2007-09-04
• Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins
  作者：Jing Li、Zhenkun Ma、Katrina Chapo、Dalai Yan、A. Simon Lynch、Charles Z. Ding

  DOI：10.1016/j.bmcl.2007.08.048

  日期：2007.10

  We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better than, rifamycin reference agents. In addition, some of the compounds retain potent activity against an intermediate rifamycin-resistant strain of Staphylococcus aureus. For instance, compound 5k exhibits an MIC of 0.12 mu g/mL against an intermediate rifamycin-resistant strain, while the rifamycin reference agents, rifampin and rifalazil, exhibit MICs of 16 mu g/mL and 2 mu g/mL, respectively, against the same strain. (c) 2007 Elsevier Ltd. All rights reserved.